20
Participants
Start Date
January 20, 2009
Primary Completion Date
March 27, 2009
Study Completion Date
March 27, 2009
0.5g SRT2104
"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
GSK Investigational Site, Merthyr Tydfill
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Sirtris, a GSK Company
INDUSTRY